1¿ù 18ÀÏ Åä¿äÀÏ
¾ÆÀ̵ð
ºñ¹Ð¹øÈ£
¾ÆÀ̵ð ã±â
Ƽ¼ÅÃ÷ (¹ÝÆÈ)
Ƽ¼ÅÃ÷ (±äÆÈ)
Ä¿Ç÷è (ÇÒÀÎ)
Á¡ÆÛ(ÆǸŸ¶°¨)
Ư°¡ÆǸŠ<==ÁøÇàÁß
ºþ¦¼¼ÀÏ
-Ä«µå°áÁ¦¿ë-
Home
> ¹®ÀÇ °Ô½ÃÆÇ ¼öÁ¤
°³ÀÎÁ¤º¸ À¯ÃâÀ» ¹æÁöÇϱâ À§ÇÏ¿© E-Mail°ú ÀüȹøÈ£´Â ÇØ´ç¶õ¿¡ ±âÀçÇÏ¿© ÁÖ½Ã¸é °¨»çÇÏ°Ú½À´Ï´Ù.
À̸§
*
*
´Â ¹Ýµå½Ã ÀÔ·ÂÇØ ÁֽʽÿÀ.
Æнº¿öµå
*
¼öÁ¤, »èÁ¦½Ã¿¡ ÇÊ¿äÇÕ´Ï´Ù.
E-Mail
*
°ø°³ÇÏÁö ¾Ê½À´Ï´Ù.
ÀüȹøÈ£
°ø°³ÇÏÁö ¾Ê½À´Ï´Ù.
Á¦¸ñ
*
³»¿ë
*
I'd like to open an account
imipramine panic disorder
For further information about these and other risks, uncertainties and factors, please review the disclosure included in the section captioned "Risk Factors" in our December 31, 2012 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 8, 2013, as updated by our quarterly reports on Form 10-Q, Current Reports on Form 8-K and other filings we have made with the SEC. You should not place undue reliance on any forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements or risk factors, whether as a result of new information, future events, changed circumstances or any other reason after the date of this press release.
¸ñ·Ï
»ç¾÷ÀÚµî·Ï¹øÈ£: 607-10-79364 ºÎ°¡Åë½Å»ç¾÷½Å°í : ºÎ»ê Á¦ 455È£
Copyright (C) 2001 Å©¸®¿¡ÀÌƼºê µðÁöÅÐ All rights reserved.